The 3 most recent market catalysts affecting $LXEO, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 22, 2026
Corporate Catalyst
Bullish
Impact 65
Lexeo Therapeutics Announces Deal To Acquire Mantle Therapeutics For $8.3M Upfront, Up To $13M In Milestones, Adding Friedreich Ataxia Programs
This headline represents a corporate catalyst for Lexeo Therapeutics, indicating strategic expansion into Friedreich Ataxia programs. The relatively small upfront payment ($8.3M) s…
Aug 12, 2026
Corporate Catalyst
Bearish
Impact 92
Lexeo Therapeutics Q2 EPS $(0.30) Misses $(0.28) Estimate
Lexeo Therapeutics announced Q2 earnings per share of $(0.30), which fell short of the consensus estimate of $(0.28). More critically, this loss represents a 50% increase from the …
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 75
Lexeo Therapeutics Says FDA Grants RMAT Designation To LX2020 Gene Therapy For PKP2-ACM Based On Interim Phase I/II HEROIC-PKP2 Data
The RMAT (Regenerative Medicine Advanced Therapy) designation is a significant regulatory milestone, indicating the FDA's recognition of LX2020's potential to address an unmet medi…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.